Introduction
============

Cancer remains a growing public health problem worldwide due to the increasing tendency of overall morbidity over the past decades. Despite the improvements in diagnostic methods and treatment techniques, the 5-year survival rate for all tumors is not optimistic, especially in developing countries.[@b1-ott-11-383],[@b2-ott-11-383] Therefore, there is an urgent need to seek reliable and feasible tumor biomarkers to assist in obtaining additional prognostic information.

HSF1 is the master regulator of proteotoxic stress response that protects cells against heat, inflammation, ischemia, and other noxious conditions. HSF1 exists primarily as an inactive monomer located in the cytoplasm and is dispensable for cellular viability under normal proteome homeostasis conditions.[@b3-ott-11-383] However, in the event of proteotoxic stress, this inactive monomeric HSF1 forms a phosphorylated trimer and then triggers the transcription of heat shock proteins (HSPs) by binding to consensus heat shock elements (HSE).[@b4-ott-11-383],[@b5-ott-11-383] HSPs such as HSP27, HSP70, and HSP90 are important molecular chaperones that promote proper folding, transportation, and degradation of proteins within cells. Simultaneously, HSF1 activation is repressed by interaction with HSP overexpression in nontumor cells. In tumor cells, however, this feedback inhibition may be ineffective.[@b6-ott-11-383],[@b7-ott-11-383]

Identification of many prognostic factors in recent years has helped more accurate prognostic prediction of tumor patients. Growing studies have demonstrated that HSF1 is overexpressed in a series of solid tumors such as esophageal squamous cell carcinoma (ESCC),[@b8-ott-11-383],[@b9-ott-11-383] breast cancer (BC),[@b10-ott-11-383],[@b11-ott-11-383] hepatocellular carcinoma (HCC),[@b12-ott-11-383]--[@b14-ott-11-383] osteosarcoma,[@b15-ott-11-383] non-small-cell lung cancer (NSCLC),[@b16-ott-11-383] and pancreatic cancer.[@b17-ott-11-383] Furthermore, evidence implies that the elevation of HSF1 expression is correlated with poor survival of tumor patients.[@b18-ott-11-383],[@b19-ott-11-383] Nevertheless, the results of these individual studies are not consistent and conclusive because of the small sample size. The aim of the present meta-analysis is to make a comprehensive analysis on potential prognostic and clinicopathological roles of HSF1 in solid tumors.

Methods
=======

Search strategy and study selection
-----------------------------------

This meta-analysis was performed by following the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria.[@b20-ott-11-383] A systematic literature search in the PubMed, Embase, and Web of Science was performed by two investigators independently (updated on June 15, 2017) by retrieving articles published in English only and using the following search terms: ("heat shock factor 1" or "HSF1") and ("tumor" or "neoplasm" or "cancer" or "carcinoma") and ("prognosis" or "prognostic"). We also manually cross-searched the citation lists of relevant studies to identify additional eligible articles. In case of overlapping cohorts, only the most recent article was considered for inclusion.

Inclusion and exclusion criteria
--------------------------------

The inclusion criteria were as follows: 1) studies that evaluated the prognostic value of HSF1 in patients with solid tumors; 2) studies in which HSF1 expression was detected in tumor tissues; 3) studies that reported hazard ratios (HRs) and 95% CI for overall survival (OS) or provided sufficient data for calculated HR and 95% CI; 4) studies that divided patients into HSF1 high expression and HSF1 low/negative (neg) expression groups, regardless of the cutoff value; and 5) studies published in English. Exclusion criteria were as follows: 1) reviews, case reports, conference abstracts, letters to the editor, and laboratory studies; 2) over-lapping or repeat analyses; and 3) insufficient data for further analysis.

Data extraction and quality assessment
--------------------------------------

Two investigators independently reviewed all eligible studies, and any disagreement between the investigators was resolved by consensus. Data extracted from the articles included the following items: first author, year of publication, study region, tumor type, cases, TNM staging (according to the *2009 International Union Against Cancer Tumour Node Metastasis Classification System*, 7th edition), detection method, cutoff value, survival outcomes, and median follow-up months. If studies did not directly provide HR for OS, the Engauge Digitizer V4.1 combined Tierney's method was utilized to estimate HR and 95% CIs from Kaplan--Meier curves.[@b21-ott-11-383] The Newcastle--Ottawa Scale (NOS) was applied to assess the quality of all included studies, and studies with an NOS score of ≥7 were considered high quality.

Statistical analysis
--------------------

Stata 12.0 (StataCorp LP, College Station, TX, USA) and RevMan software 5.3 (The Cochrane Collaboration, Oxford, UK) were used to conduct all the statistical analyses. The combined HR and 95% CI were calculated to assess the association between HSF1 expression and OS of solid tumor patients. The overall HR \>1 that failed to overlap its 95% CI indicated a poor prognosis in patients with HSF1 overexpression. In addition, the pooled odds ratio (OR) and 95% CI were used to evaluate the correlation between HSF1 expression and the clinicopathological parameters of solid tumors. Heterogeneity was measured using the Higgins *I*^2^ test. Significant heterogeneity among studies was defined as *I*^2^\>50%.[@b22-ott-11-383] Taking into account the relatively small meta-analysis, the random-effects model was always applied to provide better estimates with wider CIs.[@b23-ott-11-383] Publication bias was statistically assessed via the Egger's test and visually evaluated by funnel plots.[@b24-ott-11-383] We also performed the sensitivity analysis by sequentially omitting each individual study to validate the stability of the synthetic results. Two-tailed *P*-values \<0.05 were considered statistically significant.

Results
=======

Study selection and demographic characteristics
-----------------------------------------------

The initial search strategy identified 515 potentially relevant articles. After further screening, a total of 10 studies involving 3,159 patients were finally included in this meta-analysis.[@b8-ott-11-383]--[@b17-ott-11-383] The details of the study selection process are presented in [Figure 1](#f1-ott-11-383){ref-type="fig"}.

As for the tumor type involving ESCC, BC, HCC, osteosarcoma, NSCLC, and pancreatic cancer, HSF1 expression was detected by immunohistochemistry (IHC). All the 10 studies investigated the prognostic role of HSF1 in OS, and only three studies focused on disease-free survival (DFS).[@b9-ott-11-383],[@b15-ott-11-383],[@b16-ott-11-383] HR with the corresponding 95% CI was directly extracted through multivariate analyses in seven studies,[@b8-ott-11-383]--[@b14-ott-11-383] and HR in the remaining three studies[@b15-ott-11-383]--[@b17-ott-11-383] was calculated from Kaplan--Meier survival curves by the Tierney's methods. The quality of all the 10 studies was assessed by NOS, and the scores ranged from 5 to 8 (median 6.7), suggesting that the methodological quality was relatively high ([Table S1](#SD2-ott-11-383){ref-type="supplementary-material"}). The main characteristics of the 10 eligible studies are summarized in [Table 1](#t1-ott-11-383){ref-type="table"}.

Evidence synthesis
------------------

### Overall survival

The pooled results showed that tumor patients with positive (pos) HSF1 expression had a significantly poor OS (HR=2.09; 95% CI: 1.62--2.70; *P*\<0.001). Owing to the obvious heterogeneity in the synthesis analysis (*I*^2^=64%; 95% CI: 28%--82%), a random-effects model was applied ([Figure 2](#f2-ott-11-383){ref-type="fig"}). In addition, when the subgroup analysis was completed according to tumor type ([Figure 3](#f3-ott-11-383){ref-type="fig"}), the pooled HR revealed an association between HSF1 overexpression and unfavorable prognosis in patients with ESCC (HR=1.83; 95% CI: 1.21--2.77; *P*=0.004), BC (HR=1.52; 95% CI: 1.24--2.86; *P*\<0.001), HCC (HR=3.02; 95% CI: 1.77--5.18; *P*\<0.001), NSCLC (HR=2.19; 95% CI: 1.20--3.99; *P*=0.01), and pancreatic cancer (HR=2.58; 95% CI: 1.11--6.03; *P*=0.03) but not in osteosarcoma (HR=1.58; 95% CI: 0.47--5.35; *P*=0.46).

### Disease-free survival

Only three studies comprising 304 patients evaluated the association between HSF1 and DFS, and the HR for DFS showed that HSF1 overexpression was significantly correlated with worse DFS (HR=1.70; 95% CI=1.19--2.42; *P*=0.003; [Figure 4](#f4-ott-11-383){ref-type="fig"}). A random-effects model was used because of the small meta-analysis.

### Clinicopathological parameters

To comprehensively explore the role of HSF1 expression as a biomarker in solid tumors, we also investigated the association between HSF1 overexpression and clinicopathological parameters of the patients. As illustrated in [Figures 5](#f5-ott-11-383){ref-type="fig"} and [6](#f6-ott-11-383){ref-type="fig"}, the combined data suggested that HSF1 overexpression was significantly associated with some phenotypes of tumor aggressiveness including TNM stage (III + IV vs I + II; OR=1.84; 95% CI: 1.38--2.46; *P*\<0.001), histological grade (poor vs well + moderate; OR=2.08; 95% CI: 1.64--2.65; *P*\<0.001), lymph node metastasis (pos vs neg; OR=1.84; 95% CI: 1.30--2.60; *P*\<0.001), and vascular invasion (pos vs neg; OR=1.91; 95% CI: 1.26--2.90; *P*=0.002). However, HSF1 expression had no obvious association with the following parameters: age (≥60 vs \<60 years; OR=1.10; 95% CI: 0.75--1.62; *P*=0.63) and gender (male vs female; OR=1.18; 95% CI: 0.88--1.59; *P*=0.28). In view of the fact that the above subgroup analyses were relatively small meta-analyses and then the random-effects model was utilized. The details of the meta-analysis results are summarized in [Table 2](#t2-ott-11-383){ref-type="table"}.

Sensitivity analysis and publication bias
-----------------------------------------

We sequentially removed each single study to determine whether any individual study could affect the pooled HR for OS, and the result of random-effects sensitivity analysis was neg ([Figure S1](#SD1-ott-11-383){ref-type="supplementary-material"}). Furthermore, we performed Begg's funnel plot and Egger's test to evaluate the potential publication bias for all articles in the current meta-analysis. As shown in [Figure 7](#f7-ott-11-383){ref-type="fig"}, the shape of the funnel plot was relatively symmetrical and the *P*-value of Egger's test was 0.244, both of which indicate that there was no obvious risk of publication bias. Thus, these test results verified that the synthetic evidence was robust and reliable.

Discussion
==========

Biological organisms from bacteria to animals can respond to a wide variety of environmental stressors. When these noxious factors disrupt the state of protein homeostasis and elicit proteotoxic stress in cells, cytoprotective molecular chaperones known as HSPs are induced to counteract such stresses. It is generally accepted that the heat-shock response in eukaryotes is mediated via the regulatory effect of HSF1 on the expression of HSPs.[@b25-ott-11-383]--[@b27-ott-11-383] Accordingly, HSF1 function is not only critical to overcome the proteotoxic stress but also necessary for OS of cells and the proper development of the organisms.

Recently, a number of clinical studies have revealed that HSF1 is overexpressed in patients with various solid tumors[@b28-ott-11-383],[@b29-ott-11-383] and the elevated expression of HSF1 expression is closely associated with some phenotypes of tumor aggressiveness.[@b30-ott-11-383] These findings urge researchers to postulate whether HSF1 expression could serve as a valuable prognostic factor for better clinical decision making in tumor patients. However, no meta-analysis has been conducted to assess the prognostic and clinicopathological values of HSF1 overexpression so far.

In the present meta-analysis, we systematically evaluated the survival data from 10 independent studies involving 3,159 patients with solid tumors. The similarity in these included studies was to explore the potential prognostic role of HSF1 in solid tumor patients based on the survival analysis, and the difference between them was mainly determined by the different subjects and the methods of research, including cancer types, population distribution, sample size, cutoff value, and follow-up time. The subsequent combined results suggested that HSF1 expression was an independent unfavorable predictor for solid tumors, which was significantly negatively correlated with OS and DFS of tumor patients. Our further subgroup analysis also supports that HSF1 overexpression was significantly correlated with advanced tumor stage, poor histological grade, pos lymph node metastasis, and vascular invasion, indicating that HSF1 plays many important roles in tumor progression via regulating invasion and metastasis of malignant cells and finally affects tumor prognosis.

Furthermore, liquid biopsies (LBs) have been rapidly developed in the domain of oncology and the clinical applications will gradually expand in the near future. If HSF1 expression level can be measured in LB samples, it may exceptionally yield useful information for early diagnosis of tumors and indicate appropriate treatment strategy for individual patients based on the molecular analysis.

The results of evidence synthesis combined with published studies have demonstrated that HSF1 functions as a powerful multifaceted regulator in tumorigenesis and tumor development. In fact, the molecular mechanisms of HSF1 promoted the malignant phenotypic tendency of cancer were inconsistent in each study and the main molecular mechanisms are as follows. First, HSF1 activation promotes the expression of HSPs including HSP27, HSP70, and HSP90, thus facilitating transition of cells from normal to malignant phenotypes.[@b31-ott-11-383]--[@b33-ott-11-383] Second, there is already evidence that a variety of signaling pathways are triggered by HSF1 in solid tumors.[@b12-ott-11-383],[@b30-ott-11-383],[@b33-ott-11-383]--[@b36-ott-11-383] These signaling pathways are coordinated with each other to drive tumorigenesis, tumor development, epithelial-to-mesenchymal transition (EMT), proliferation, invasion, metastasis, angiogenesis, and antiapoptosis of tumor cells. In addition, studies have indicated that HSF1 regulates intracellular metabolism reprogramming, especially glycolysis and lipid metabolism.[@b37-ott-11-383],[@b38-ott-11-383] The reprogramming of metabolism patterns allows tumor cells to meet the massive energy demands and the biosynthetic needs of malignant growth. Finally, HSF1 also possesses the ability to upregulate or downregulate the expression of microRNAs and long noncoding RNAs, both of which play critical roles in tumor progression.[@b39-ott-11-383],[@b40-ott-11-383]

Nevertheless, this meta-analysis has some limitations. First, given the limited number of included studies for a comprehensive analysis, the pooled conclusions may be less powerful and should be interpreted with caution, especially in osteosarcoma. Second, all the 10 eligible studies were of retrospective nature. In addition, three studies did not directly provide HR and 95% CI; rather they extracted the data from survival curves, which may introduce bias. Third, there existed a high level of undetected heterogeneity among subgroup analyses, which we suppose may be attributed to the smaller numbers of studies, different tumor types, or pos cutoff values. However, we could not completely eliminate the heterogeneity because only summarized data could be used. Larger multicenter prospective studies are required to further verify the prognostic and clinicopathological significances of HSF1 expression in solid tumors.

Conclusion
==========

The findings of our meta-analysis provide preliminary evidence that HSF1overexpression is associated with unfavorable prognosis in various solid tumors. HSF1 may prove to be a promising prognostic biomarker and a potential specific therapeutic target for solid tumors. Of course, more investigations on molecular mechanisms underlying the regulatory effect of HSF1 are required to verify our postulation.

Supplementary materials
=======================

###### 

The random-effects sensitivity analysis of the OS.

**Abbreviation:** OS, overall survival.

###### 

Evaluations of the qualities of the included studies based on the Newcastle--Ottawa Scale

  Author                                    Selection   Comparability   Outcome   Total                                 
  ----------------------------------------- ----------- --------------- --------- ------- -------- ------ ------ ------ ---
  Tsukao et al[@b41-ott-11-383]             ^\*^        ^\*^            ^\*^              ^\*\*^   ^\*^   ^\*^   ^\*^   8
  Liao et al[@b42-ott-11-383]               ^\*^        ^\*^            ^\*^              ^\*^     ^\*^          ^\*^   6
  Gokmen-Polar and Badve[@b43-ott-11-383]   ^\*^        ^\*^            ^\*^              ^\*^     ^\*^          ^\*^   6
  Santagata et al[@b44-ott-11-383]          ^\*^        ^\*^            ^\*^              ^\*\*^   ^\*^   ^\*^   ^\*^   8
  Chuma et al[@b45-ott-11-383]              ^\*^        ^\*^            ^\*^              ^\*\*^   ^\*^   ^\*^   ^\*^   8
  Zhang et al[@b46-ott-11-383]              ^\*^        ^\*^            ^\*^              ^\*^     ^\*^   ^\*^   ^\*^   7
  Fang et al[@b47-ott-11-383]               ^\*^        ^\*^            ^\*^              ^\*^     ^\*^          ^\*^   6
  Zhou et al[@b48-ott-11-383]               ^\*^        ^\*^            ^\*^              ^\*^     ^\*^                 5
  Cui et al[@b49-ott-11-383]                ^\*^        ^\*^            ^\*^              ^\*^     ^\*^   ^\*^   ^\*^   7
  Liang et al[@b50-ott-11-383]              ^\*^        ^\*^            ^\*^              ^\*^     ^\*^          ^\*^   6

**Note:** The "^\*^" denotes 1 point and "^\*\*^" denotes 2 points.
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![A flow diagram of the study selection process.\
**Abbreviations:** HSF1, heat shock factor 1; IHC, immunohistochemistry; OS, overall survival.](ott-11-383Fig1){#f1-ott-11-383}

![Forest plot of studies evaluating the association between HSF1 expression level and OS in patients with solid tumors.\
**Abbreviations:** HSF1, heat shock factor 1; IHC, immunohistochemistry; OS, overall survival; SE, standard error; IV, inverse variance; M--H, Mantel--Haenszel.](ott-11-383Fig2){#f2-ott-11-383}

![Forest plot describing the HRs and their corresponding CIs by tumor type subgroups.\
**Abbreviations:** HRs, hazard ratios; IV, inverse variance.](ott-11-383Fig3){#f3-ott-11-383}

![Forest plot showing the correlation between HSF1 overexpression and disease-free survival in patients with solid tumors.\
**Abbreviations:** HSF1, heat shock factor 1; HRs, hazard ratios; IV, inverse variance.](ott-11-383Fig4){#f4-ott-11-383}

![Forest plots of ORs for the associations between HSF1 overexpression and clinicopathological features in solid tumors. **Note:** (**A**) TNM stage, (**B**) histological grade, (**C**) lymph node metastasis, and (**D**) vascular invasion.\
**Abbreviations:** HSF1, heat shock factor 1; ORs, odds ratios.](ott-11-383Fig5){#f5-ott-11-383}

![Forest plots of ORs for the associations between HSF1 overexpression and clinicopathological features in solid tumors. **Note:** (**A**) Age and (**B**) gender.\
**Abbreviations:** HSF1, heat shock factor 1; ORs, odds ratios.](ott-11-383Fig6){#f6-ott-11-383}

![Begg's funnel plot and Egger's test evaluating the publication bias of the included studies.\
**Abbreviation:** HR, hazard ratio.](ott-11-383Fig7){#f7-ott-11-383}

###### 

Main characteristics of the included studies

  Author                                    Year   Country   Cancer type         Case    HSF1 positive (%)   TNM stage   Detection method   Cutoff value (positive)                                             Outcome   MFu time (months)   NOS score
  ----------------------------------------- ------ --------- ------------------- ------- ------------------- ----------- ------------------ ------------------------------------------------------------------- --------- ------------------- -----------
  Tsukao et al[@b8-ott-11-383]              2017   Japan     ESCC                212     109 (51.4)          I--IV       IHC                Score ≥2 (range 0--3)[a](#tfn1-ott-11-383){ref-type="table-fn"}     OS        60                  8
  Liao et al[@b9-ott-11-383]                2015   China     ESCC                134     76 (56.7)           I--IV       IHC                Score ≥7 (range 0--12)[b](#tfn2-ott-11-383){ref-type="table-fn"}    OS/DFS    25                  6
  Gokmen-Polar and Badve[@b10-ott-11-383]   2016   USA       BC                  210     161 (76.7)          NR          IHC                NR                                                                  OS        NR                  6
  Santagata et al[@b11-ott-11-383]          2011   USA       BC                  1,841   1,437 (78.1)        I--III      IHC                Score ≥1 (range 0--2)[a](#tfn1-ott-11-383){ref-type="table-fn"}     OS        179                 8
  Chuma et al[@b12-ott-11-383]              2014   Japan     HCC                 226     115 (50.9)          I--IV       IHC                Positively stained cells \>30%                                      OS        60                  8
  Zhang et al[@b13-ott-11-383]              2013   China     HCC                 103     48 (46.6)           I--III      IHC                Score ≥8 (range 0--15)[b](#tfn2-ott-11-383){ref-type="table-fn"}    OS        38                  7
  Fang et al[@b14-ott-11-383]               2012   China     HCC                 213     105 (49.3)          NR          IHC                Score ≥2 (range 0--3)[a](#tfn1-ott-11-383){ref-type="table-fn"}     OS        25                  6
  Zhou et al[@b15-ott-11-383]               2017   China     Osteosarcoma        65      37 (56.9)           NR          IHC                Score ≥2 (rang of 0--3)[a](#tfn1-ott-11-383){ref-type="table-fn"}   OS/DFS    NR                  5
  Cui et al[@b16-ott-11-383]                2015   China     NSCLC               105     45 (42.9)           I--III      IHC                Score ≥4 (range 0--7)[b](#tfn2-ott-11-383){ref-type="table-fn"}     OS/DFS    60                  7
  Liang et al[@b17-ott-11-383]              2017   China     Pancreatic cancer   50      37 (74.0)           I--IV       IHC                Positively stained cells \>25%                                      OS        NR                  6

**Notes:**

The immunohistochemical scoring system was based on the staining intensity.

The immunohistochemical scoring system was based on the proportion of positively stained cells combined with the staining intensity.

**Abbreviations:** BC, breast cancer; DFS, disease-free survival; ESCC, esophageal squamous cell carcinoma; HCC, hepatocellular carcinoma; HSF1, heat shock factor 1; IHC, immunohistochemistry; NSCLC, non-small-cell lung cancer; NOS, Newcastle--Ottawa Scale; NR, not reported; MFu, median Follow-up; OS, overall survival.

###### 

Main meta-analysis results of HSF1 overexpression in patients with solid tumors

  Analysis                                       Number of studies   Number of patients   HR (95% CI)         *P*-value   Heterogeneity   
  ---------------------------------------------- ------------------- -------------------- ------------------- ----------- --------------- -------
  Overall survival                               10                  3,159                2.09 (1.62--2.70)   \<0.001     64              0.003
  Disease-free survival                          3                   304                  1.70 (1.19--2.42)   0.003       0               0.58
  **Clinicopathological parameters**                                                      **OR (95% CI)**                                 
  TNM stage (III + IV vs I + II)                 6                   2,621                1.71 (1.37--2.14)   \<0.001     12              0.34
  Histological grade (poor vs well + moderate)   5                   2,409                2.10 (1.66--2.67)   \<0.001     0               0.57
  Lymph node metastasis (pos vs neg)             4                   2,292                1.63 (1.32--2.00)   \<0.001     42              0.16
  Vascular invasion (pos vs neg)                 3                   542                  1.94 (1.32--2.84)   \<0.001     13              0.32
  Age (≥60 vs \<60) (years)                      3                   544                  1.10 (0.75--1.62)   0.63        0               0.95
  Gender (male vs female)                        7                   1,058                1.24 (0.92--1.69)   0.16        0               0.70

**Abbreviations:** HR, hazard ratio; neg, negative; OR, odds ratio; pos, positive.
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